Roles of ceramides in development of insulin resistance (WP5181)
Homo sapiens
Ceramides and insulin resistance are connectedd. Ceramides are accumulated in tissues due to an excess of saturated fatty acids. In obese subjects, the amount of ceramides found in skeletal muscles is nearly double that of healthy subjects. Ceramides are produced mostly by the sphingolipid pathway. Besides the sphingolipid pathway, ceramides are also produced by the hydrolysis of sphingomyelin with the catalysis of nSMase2. In the cell, ceramides play a role in insulin resistance. Ceramides inhibit the binding of PDX-1 and MAFA transcription factors to insulin promoter. Ceramides cause ER stress, which activates extracellular signal-regulated kinase MAPK8 and EIF2AK2. This leads to the upregulation of serine phosphorylation while downregulating tyrosine phosphorylation of IRS-1. That, in turn, leads to the inhibition of recruitment and activation of PI3K. This leads to a downregulation in AKT1, an enzyme that stimulates the translocation of GLUT4. Ceramides also impair mitochondria functions and inhibit fatty acid oxidation, eventually leading to ROS and inflammation. Ceramides activate protein PP2A, which promotes the dephosphorylation of AKT1. PKCζ is also activated by ceramides to inhibit the activity of AKT1. Moreover, palmitoyl-CoA downregulates the phosphorylation of AMPK, which leads to the increase of ER stress in the cell and decreases in fatty acid oxidation. On the other hand, oleic acid inhibits the downregulation of AMPK caused by palmitoyl-CoA. Oleic acid also increases the expression of CPT1B, stimulating the fatty acid oxidation to reduce the inflammation in the cell.
Authors
Giang Nguyen , Eric Weitz , Luc Hooglugt , Denise Slenter , and Egon WillighagenActivity
Discuss this pathway
Check for ongoing discussions or start your own.
Cited In
Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.
Organisms
Homo sapiensCommunities
Annotations
Pathway Ontology
type 2 diabetes mellitus pathway insulin signaling pathwayCell Type Ontology
cell of skeletal muscleDisease Ontology
atherosclerosis diabetes mellitus obesityLabel | Type | Compact URI | Comment |
---|---|---|---|
ROS | Metabolite | chebi:26523 | |
Palmitate | Metabolite | chebi:15756 | |
Sphingomyelin | Metabolite | chebi:89490 | |
ceramide | Metabolite | chebi:52639 | |
Palmitoyl-CoA | Metabolite | chebi:15525 | |
glucose | Metabolite | chebi:17234 | |
Oleic acid | Metabolite | hmdb:HMDB0000207 | |
OA | Metabolite | hmdb:HMDB0000207 | Oleic acid |
MAPK8 | GeneProduct | ensembl:ENSG00000107643 | |
AKT1 | GeneProduct | ensembl:ENSG00000142208 | |
EIF2AK2 | GeneProduct | ensembl:ENSG00000055332 | Eukaryotic Translation Initiation Factor 2 Alpha Kinase 2 |
PDX1 | GeneProduct | uniprot:P52945 | |
TRAF1 | Protein | uniprot:Q13077 | |
CPT1B | Protein | uniprot:Q92523 | |
RPS6KB1 | Protein | uniprot:P23443 | |
ACSL1 | Protein | uniprot:P33121 | The activation is catalyzed by palmitoyl-coenzyme A synthetase |
TNFR | Protein | uniprot:P19438 | |
CD36/FAT | Protein | uniprot:P16671 | |
GLUT4 | Protein | uniprot:P14672 | |
ERN1 | Protein | uniprot:O75460 | |
IRS-1 | Protein | uniprot:P35568 | |
IRS-2 | Protein | uniprot:Q9Y4H2 | |
INSR | Protein | uniprot:P06213 | |
PP2A | Protein | uniprot:P67775 | Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform |
PKCzeta | Protein | uniprot:Q05513 | Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform |
TNF-alpha | Protein | uniprot:P01375 | |
PI3K | Protein | uniprot:P27986 | PI3K subunit alpha |
MAFA | Protein | uniprot:Q8NHW3 | |
Insulin | Protein | uniprot:P01308 | |
nSMase2 | Protein | uniprot:Q9NY59 | Sphingomyelin phosphodiesterase 2 |
AMPK | Protein | uniprot:Q9UGI9 |
References
- Palmitoyl-coenzyme A synthetase. Mechanism of reaction. Bar-Tana J, Rose G, Brandes R, Shapiro B. Biochem J. 1973 Feb;131(2):199–209. PubMed Europe PMC Scholia
- Association of the CPT1B gene with skeletal muscle fat infiltration in Afro-Caribbean men. Miljkovic I, Yerges LM, Li H, Gordon CL, Goodpaster BH, Kuller LH, et al. Obesity (Silver Spring). 2009 Jul;17(7):1396–401. PubMed Europe PMC Scholia
- Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. Kaneto H, Katakami N, Matsuhisa M, Matsuoka T aki. Mediators Inflamm. 2010;2010:453892. PubMed Europe PMC Scholia
- Oleic acid stimulates complete oxidation of fatty acids through protein kinase A-dependent activation of SIRT1-PGC1α complex. Lim JH, Gerhart-Hines Z, Dominy JE, Lee Y, Kim S, Tabata M, et al. J Biol Chem. 2013 Mar 8;288(10):7117–26. PubMed Europe PMC Scholia
- Plasma ceramides target skeletal muscle in type 2 diabetes. Kirwan JP. Diabetes. 2013 Feb;62(2):352–4. PubMed Europe PMC Scholia
- Localisation of AMPK γ subunits in cardiac and skeletal muscles. Pinter K, Grignani RT, Watkins H, Redwood C. J Muscle Res Cell Motil. 2013 Dec;34(5–6):369–78. PubMed Europe PMC Scholia
- Targeting sphingolipid metabolism in the treatment of obesity/type 2 diabetes. Bellini L, Campana M, Mahfouz R, Carlier A, Véret J, Magnan C, et al. Expert Opin Ther Targets. 2015;19(8):1037–50. PubMed Europe PMC Scholia
- Targeting endoplasmic reticulum stress in insulin resistance. Salvadó L, Palomer X, Barroso E, Vázquez-Carrera M. Trends Endocrinol Metab. 2015 Aug;26(8):438–48. PubMed Europe PMC Scholia
- Palmitic and Oleic Acid: The Yin and Yang of Fatty Acids in Type 2 Diabetes Mellitus. Palomer X, Pizarro-Delgado J, Barroso E, Vázquez-Carrera M. Trends Endocrinol Metab. 2018 Mar;29(3):178–90. PubMed Europe PMC Scholia
- Neutral sphingomyelinase 2 regulates inflammatory responses in monocytes/macrophages induced by TNF-α. Al-Rashed F, Ahmad Z, Thomas R, Melhem M, Snider AJ, Obeid LM, et al. Sci Rep. 2020 Oct 8;10(1):16802. PubMed Europe PMC Scholia
- Neutral sphingomyelinase-2 and cardiometabolic diseases. Sindhu S, Leung YH, Arefanian H, Madiraju SRM, Al-Mulla F, Ahmad R, et al. Obes Rev. 2021 Aug;22(8):e13248. PubMed Europe PMC Scholia